Oxford-Harrington Rare Disease Centre Opens 2025 Call for Proposals
Scholar Award Accelerates Novel Therapies for Rare Diseases
The OHC's 2025 Rare Disease Scholar Award seeks novel approaches to treat rare diseases, with a focus on neurological disorders, developmental and metabolic disorders, and rare cancers. Applications directed to other rare, genetic indications with a high unmet need are also of interest. Any therapeutic modality will be considered. Intellectual property rights are retained by the award recipient or their institution.
Researchers in the US,
- Guaranteed grant award of
USD$100,000 for US- andCanada -based awardees and £100,000 forUK -based awardees - One year of therapeutics development support and project management with potential to renew for a second year based on milestones met
- Access to core facilities and infrastructure including oligonucleotide synthesis and screening, small molecule and protein platforms, cell and gene therapy facilities
- Opportunity to compete for acceleration funds up to
USD$300,000 / £250,000 - Opportunity to qualify for investment funds up to
USD$1,000,000 according to project requirements - Invitation to present at a Harrington Discovery Institute or Oxford-Harrington Centre Symposium
Award recipients will be selected by the OHC Scientific Advisory Council and announced in
The deadline to submit a full application is
To learn more and apply: OxfordHarrington.org/Award
View original content:https://www.prnewswire.com/news-releases/oxford-harrington-rare-disease-centre-opens-2025-call-for-proposals-302351266.html
SOURCE Harrington Discovery Institute
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flex to Participate in Upcoming Investor Conference
- Docusign Announces Second Quarter Fiscal 2027 Financial Results
- Health & Medicare Names CoreAge Rx the #1 Supplement Brand for Targeted Nutrition and Recovery
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share